help button home button Am J Pathol The FASEB Journal
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louden, C. S.
Right arrow Articles by Schwartz, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louden, C. S.
Right arrow Articles by Schwartz, L. W.
(American Journal of Pathology. 2000;157:123-134.)
© 2000 American Society for Investigative Pathology

Regular Articles

Endothelin Receptor Subtype Distribution Predisposes Coronary Arteries to Damage

Calvert S. Louden*, Ponnal Nambi{dagger}, Mark A. Pullen{dagger}, Roberta A. Thomas*, Lauren A. Tierney*, Henk A. Solleveld* and Lester W. Schwartz*

From the Departments of Safety Assessment*
and Renal Pharmacology,{dagger}
SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Several vasoactive drugs that lower blood pressure and increase heart rate induce regional cardiotoxicity in the dog, most frequently of right coronary arteries and right atrium. The basis for this selective damage is thought to result from local changes in vascular tone and blood flow. Administration of an endothelin receptor antagonist (ETRA, SB 209670) to dogs induced damage most frequent and severe in the right coronary artery and right atrium. Because site predisposition may correlate with distribution of vasoactive receptors, the objectives of this study were to map endothelin (ET) receptor distribution and density within regions of dog heart using both gene (mRNA) and protein expression endpoints for dog ETA and ETB receptors, and, additionally, correlate ET receptor subtype density with regional cardiac blood flow. A 10- to 15-mmHg reduction in mean arterial pressure with a concomitant increase in heart rate (10–20%), a six- and twofold increase in regional blood flow to the right and left atrium, respectively, and acute hemorrhage, medial necrosis, and inflammation were observed in the right coronary arteries and arteries of the right atrium after ETRA infusion for 5 days. Radioligand protein binding to quantify both ET receptors in normal dog heart indicated a twofold greater density of ET receptors in atrial regions versus ventricular regions. Importantly, ET receptor density in coronary arteries was markedly (about five- to sixfold) increased above that in atrial or ventricular tissues. ET receptor subtype characterization indicated ETB receptors were three times more prevalent in right coronary arteries compared to left coronary arteries and in situ hybridization confirmed localization of ETB in vascular smooth muscle. ETA receptor density was comparable in right and left coronary arteries. Quantitative real-time polymerase chain reaction for ETA and ETB receptor mRNA transcripts supported the site prevalence for message distribution. Consequently, the composite of protein and message expression profiles for ETA and ETB receptors indicated a disproportionate distribution of ETB receptors within right coronary artery of dog and this, along with functional measures of blood flow after ETRA infusion indicated a predisposition for exaggerated pharmacological responses and subsequent damage to right coronary arteries by ET and/or ETRAs.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Cardiovascular toxicity frequently occurs at specific anatomical sites and generally has characteristic histopathological features. Lesion location and the combination of vascular and myocardial damage is an indicator of vasopressor or vasodilator activity of an insulting agent.1 Various vasodilators, when given to dogs induce hemorrhage, medial necrosis, and acute inflammation predominantly of the right coronary arteries and/or right atrium.1-5 For example, when endothelin receptor antagonists (ETRA) are given to dogs, characteristic lesions occur in the atrium and coronary arteries, even in the absence of meaningful clinical signs.6,7 Because endothelin (ET) is a potent vasoconstrictor,8,9 blockade of ET receptors should mediate vasodilation. However, the final biological outcome of ET receptor blockade is variable and influenced by a several factors, including (i) ET receptor subtypes involved, (ii) association of ET subtypes with specific cells (endothelium or vascular smooth muscle), (iii) ratios of ET receptor subtypes at affected sites, and (iv) specific signal transduction systems conducting responses in particular species or tissue types. Two major ET receptors, ETA and ETB, are recognized; however, pharmacological evidence suggests additional subtypes are present but not well characterized.10-15 Classically, vascular smooth muscle cells express ET receptors ETA and ETB,12,16 whereas endothelial cells express only ETB.15 In general, ETA mediates vasoconstriction and ETB receptors on endothelium, through release of nitric oxide, indirectly mediate vasorelaxation.17,18 However, an ETB receptor subtype of vascular smooth muscle directly mediates smooth muscle contraction.14,19-23 In the dog, ETB receptors of coronary arteries are potent vasoconstrictors.22,24,25

SB 209670, a novel nonpeptide ETRA, has high affinity for human cloned ETA and ETB receptors (KiS of 0.2 and 18 nmol/L, respectively) which, in a variety of model systems, competitively inhibits both ETA- and ETB-mediated arterial contractions.26 SB 209670, when given to dogs as an intravenous infusion for 5 days (50 µg/kg/minute), increased heart rate (HR), decreased mean arterial pressure (MAP), and caused atrial hemorrhage and acute coronary arterial injury (medial hemorrhage, necrosis, and perivascular inflammation), predominantly of the right heart. These right heart lesions after administration of selective ETRA indicated that ET receptors predispose specific locations to damage. The objectives of this study were, first, to quantify ET receptor subtypes in specific anatomical regions of the normal dog heart; second, to quantify regional blood flow in dog heart during periods of ET receptor blockade by SB 209670 as a measure of vascular function; and third, to correlate ET receptor density with regional blood flow and severity and frequency of cardiovascular damage. ET receptor mRNA and protein expression were quantified in selected areas of dog heart including right and left atria, ventricles, and coronary arteries. Quantitative real time reverse transcriptase-polymerase chain reaction (RT-PCR) and radiolabeled ligands were used to measure ETA and ETB mRNA, and ETA and ETB receptor proteins, respectively. Dog-specific radiolabeled ET receptor riboprobes in conjunction with in situ hybridization were used to anatomically characterize receptor distribution within dog coronary arteries. Right and left atria and ventricular blood flow was determined both before and after administration of SB 209670 using fluorescent microspheres.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals

Purebred beagle dogs 12 to 14 months old (Marshall Farms, Inc., North Rose, NY) were used. Dogs were housed individually in stainless steel cages and fed Purina Certified Canine Diet 5007 (Purina Mills Inc., Richmond, IN) and water ad libitum. Animal care, husbandry, and cage specifications conformed to the current guidelines of ILAR/AALAC and the "Guide for the Care and Use of Laboratory Animals." In preparation for intravenous infusion, dogs received a jugular catheter and were jacketed for protection.

Test Article, Vehicle, and Dose Regimen

Dogs (3 males and 3 females/group) were given 50 µg/kg/minute SB 209670 (5 mg/ml) or 0.9% sodium chloride (saline) as a continuous intravenous infusion for up to 5 days. The solutions were sterile-filtered through a 0.22-µm Sterivex-GV filter into clear PVC Viaflex infusion bags and an ambulatory peristaltic pump (CADD plus, Model 5400, Sims Deltec, St. Paul, MN) was used for delivery through polyvinyl catheters. The study design is shown in Table 1 .


View this table:
[in this window]
[in a new window]
  		Table 1. Study Design, Toxicokinetic Data, and Frequency of Coronary Arterial Lesions

 
Measurement of Blood Pressure and Heart Rate

A series of MAP and HR plots were obtained before, during, and after dosing using Dataquest (Data Sciences International, St. Paul, MN) from surgically implanted radiotelemetry transmitters. Plots were constructed from averaged intervals. Average values, standard deviations, number of observations, and minimum and maximum values were summarized for 24-hour time periods.

Determination of Regional Myocardial Blood Flow

Regional myocardial blood flow (RBF) was measured using color-coated fluorescent microspheres27-29 before and after infusion of ETRA (SB 209670). Briefly, multiple sets of NuFlow microspheres (15 µm in diameter, Triton Technology, San Diego, CA), each having a distinct fluorescent color emission, were supplied in sterile saline containing 0.05% Tween 80 and 0.01% Thimersal. Microsphere suspensions were diluted in 0.5% (w/v) dextrose and microspheres/100 µl quantified. Before ETRA infusion, dogs were pretreated with 0.01% Tween 80 to preclude Tween-related hemodynamic effects during study.30 Dogs were also acclimated to stabilize MAP and HR before microsphere injection. Vascular access ports (VAP) to the left atrium were used for microsphere injection and reference blood samples obtained from an aortic VAP immediately after microsphere administration. One color-set of microspheres was given on day 1, before ETRA infusion, and another color-set was given on day 5 during completion of ETRA infusion, allowing each dog to serve as its own control, thereby reducing interanimal variability. Regional myocardial tissues were collected at necropsy, weighed, homogenized, and analyzed by flow cytometry for quantification of each set of microspheres per gram of tissue.

Toxicokinetics of SB 209670

Serial jugular vein blood samples were collected at 0, 2, 4, and 8 hours of ETRA infusion and at the end of days 1, 2, 3, 4, and 5 to analyze SB 209670 concentration using a high pressure liquid chromatography method.

Tissue Collection and Histopathology

Heart and coronary arteries were examined at necropsy. Atria, ventricles, and coronary arteries were collected and identified as right or left chambers; this identity was maintained throughout processing and examination. Light microscopic assessment was completed after paraffin embedding and staining with hematoxylin and eosin. Expression of ETA and ETB receptor mRNA was localized using isotopic in situ hybridization procedures.31 [33P]-UTP-labeled riboprobes were synthesized from PCR-generated cDNA templates containing flanking T3 and T7 promoter sequences for sense and antisense riboprobes, respectively. Primer sequences are illustrated in Table 2 .


View this table:
[in this window]
[in a new window]
  		Table 2. Primers and Fluorogenic Probes

 
ET Receptor Binding Studies

Membrane Preparation and Radioligand Binding

Regions of femoral, right (RCA) and left (LCA) coronary arteries, and heart (right and left atria and ventricles) were collected from untreated dogs (n = 4). Cell membranes were prepared following the procedure of Brooks et al32 for radioligand binding studies. Briefly, dissected tissues were homogenized in buffer containing 20 mmol/L Tris-HCl pH 7.5, 5 mmol/L EDTA, 0.25 mol/L sucrose, 100 µg/ml phenylmethyl sulfonyl fluoride, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. After low-speed centrifugation (1000 x g) for 10 minutes at 4°C, supernatants were collected and centrifuged again for 30 minutes at 45,000 x g at 4°C. Resulting pellets were re-suspended in buffer containing 50 mmol/L Tris-HCl, pH 7.5, and 20 mmol/L MgCl2 and frozen.

[125I]-ET-1 (specific activity 2200 Ci/mmol) and [125I]-ET-3 (specific activity 2200 Ci/mmol) were obtained from New England Nuclear (Boston, MA); unlabeled ET-1 and ET-3 were obtained from American Peptides (Sunnyvale, CA). For radioligand binding, 0.3 nmol/L of [125I]-ET-1 or [125I]-ET-3 was added to membrane preparations (5–10 µg/tube) and incubated at 30°C for 60 minutes. Reactions were quenched with cold buffer. Bound and free ligands were separated by filtering and counted using a {gamma} counter. Nonspecific binding was determined in the presence of 100 nmol/L unlabeled ET-1 or ET-3. Because ET-1 binds to both ETA and ETB receptors and ET-3 binds only to ETB, ETB receptor density was measured directly and ETA receptor density was calculated.

Tissue Collection and RNA Isolation

Using normal dog tissues, total RNA was isolated from right coronary artery (RCA) and left coronary artery (LCA), atrial and ventricular myocardium, kidney, and femoral artery. RNA was treated with 0.8 units RQ1 RNase-free DNase (Promega, Madison, WI) before extraction with phenol/chloroform to reduce DNA contamination.33 RNA integrity was verified by fractionation on 1% agarose-formaldehyde gel containing 0.5 µg/ml of ethidium bromide followed by ultraviolet visualization.

Cloning of Partial Coding Sequence for Canine ETA Receptor

To partially clone the dog ETA receptor gene, PCR primers were designed from conserved regions (GenBank Accession numbers U20577, S67127, X57765, M60786, AF039892, U06633) using the Basic Local Alignment Search Tool (National Center for Biotechnological Information, Washington, D.C.). Sequences of forward and reverse primers were 5'-AAGGACTGGTGGCT-3' and 5'-GGCATGACTGGAAA-3', respectively. Based on previous reports describing ETA receptor localization in the dog,32 RT-PCR was performed using total RNA isolated from the dog kidney. Single-stranded cDNA synthesis was accomplished using the Superscript pre-amplification system for first strand cDNA synthesis (Life Technologies, Gaithersburg, MD); random hexamers were used to prime cDNA synthesis. PCR was performed in a total volume of 50 µl consisting of 1.5 mmol/L MgCl2, 200 µmol/L each ATP, CTP, GTP, and TTP, 200 nmol/L of each primer, 2.5 U of AmpliTaq DNA polymerase (PE Applied Biosystems, Foster City, CA) and 1x PCR buffer containing 20 mmol/L Tris-HCl, pH 8.4, and 50 mmol/L KCl. All reactions were performed in a PE Applied Biosystems GeneAmp PCR System 2400. PCR products were analyzed by gel electrophoresis and subsequently recovered using the QIAquick gel extraction kit (Qiagen Inc., Valencia, CA). Purified PCR products were ligated into a bidirectional TA cloning vector, pCRII, and transferred into INV{alpha}F' cells (Invitrogen, San Diego, CA). Minipreps of 20 clones were prepared using the Wizard Plus Minipreps DNA Purification System (Promega). Clones containing inserts were identified by restriction enzyme digestion with EcoRI (Promega) and subsequent agarose gel analysis. Sequencing and analysis of clones were performed using PE Applied Biosystems 373A Automated DNA Sequencer and Basic Local Alignment Search Tool and Lasergene biocomputing software for Windows (DNASTAR Inc., Madison, WI). The nucleic acid sequence obtained had a 93% homology to the human ETA receptor gene (Figure 1) .34 This cloned ETA sequence was subsequently used in the quantitative real-time PCR (Taqman) and in situ hybridization analysis. Primer and probe sequences for dog ETA and ETB receptor genes and ß-actin genes are shown in Table 2 .



View larger version (32K):
[in this window]
[in a new window]
  		Figure 1. Partial nucleotide and amino acid sequences for the dog ETA receptor is shown aligned with homologous region of the human ETA receptor, the non-identical region at the amino acid level are shaded.

 
Quantitative Real-Time RT-PCR Analysis

Single-stranded cDNA templates were made from the selected tissues and Taqman analysis used to determine relative differences in PCR products.35,36 Briefly, fluorogenic probes designed to hybridize to the amplicon had a reporter dye (6-FAM) conjugated to the 5' end and a quencher dye (TAMRA) conjugated to the 3' end. Fluorescence for each cycle was quantitatively analyzed on an ABI Prism 7700 Sequence Detection System (PE Applied Biosystems). Each reaction consisted of 1x Taqman Buffer A, 200 µmol/L each of dATP, dCTP, and dGTP, 400 µmol/L dUTP, 100 nmol/L fluorogenic probe, 200 nmol/L each of forward and reverse primers, 0.01 U/µl AmpErase uracil-N-glycosylase, 0.025 U/µl Taq Gold (PE Applied Biosystems), and either 0.5, 1, 10, 100, or 200 ng of template. Standard curves were generated from dog femoral artery cDNA. ß-Actin was used as an endogenous control and active reference to normalize quantities of cDNA. Target quantities were normalized to ß-actin and all quantities expressed as a fold difference from the femoral artery value.

Statistical Methods and Analyses

Statistical analyses of RBF, HR, and MAP were completed. Baseline (predosing) and post-dosing values from control and drug-treated dogs were analyzed using a repeated measures analysis of variance and pairwise comparisons to determine drug effect. Differences were considered significant if the P value was less than 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Hemodynamic Parameters in Dogs Given ETRA

Intravenous infusion of SB 209670 induced a slight but persistent decrease in MAP (10–15 mmHg), which was apparent 1 to 3 hours after start of infusion. This decrease in MAP persisted for 24 hours (last time point measured) after infusion termination (Figure 2) , and the magnitude of change was considered within normal physiological range for MAP in the dog. During the 5-day infusion period, HR increased over time and was maximally increased (10 to 20% over pre-infusion values) on day 4 (Figure 2) . A statistically significant increase in HR (P < 0.05) above baseline values occurred on days 2–5. HR returned to near pre-infusion values 24 hours after termination of infusion.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 2. Mean arterial pressure (MAP; A) and heart rate (HR; B) from control and ETRA infused dogs. *P < 0.05 (statistically significant increase).

 
Regional Blood Flow (RBF)

Quantification of RBF in right and left atria and ventricles is summarized in Figure 3 . Baseline values represent flow measured on day 1, just before the start of ETRA infusion, and was compared to flow measure after 5 days of infusion. Infusion of vehicle for 5 days did not alter flow characteristics from those of day 1 (Figure 3 , insert). Baseline flow in ventricular chambers was approximately three- to fourfold greater than baseline flow in atria. After ETRA infusion for 5 days, right atrial blood flow increased (P < 0.05) approximately sixfold when compared to pre-infusion values (Figure 3) . In contrast, there were only marginal increases in blood flow to other cardiac chambers. The duration of ETRA infusion also appeared to influence myocardial flow rates, since flow was increased only 0.5- to 1.8-fold after only 3 hours of SB 207960 infusion (data not shown) but increased up to sixfold by day 5.



View larger version (19K):
[in this window]
[in a new window]
  		Figure 3. Regional blood flow from vehicle- and ETRA-infused dogs. Note marked increase in right atrial blood flow after ETRA infusion for 5 days. *P < 0.05 (statistically significant increase). No change was observed in vehicle-infused dogs (inset).

 
Pathology

All dogs given 50 µg/kg/minute SB 209670 for 5 days had heart lesions readily recognized at necropsy. The lesions consisted of petechial hemorrhages in the right atrium and atrial appendage and/or coronary groove. Changes were infrequent in the left heart (Figure 4, A and B) and there were no lesions in the septum or ventricles. There were no macroscopic observations in hearts of dogs given 10 or 50 µg/kg/minutes SB 209670 for either 12 or 24 hours. Changes were most prevalent in large extramural coronary arteries, both right and left branches. Subepicardial and intramural branches of the RCA were also damaged, but not branches of the LCA. Lesions were characterized histologically by multifocal hemorrhage, segmental medial necrosis, acute inflammation, and perivascular edema (Figure 4, C and D) . Medial necrosis of severely affected arteries was generally associated with hemorrhage into the vascular wall and perivascular tissues and accumulations of neutrophils. The more extensive vascular lesions were associated with perivascular hemorrhage, which extended into adjacent atrial tissue and widely separated atrial cardiomyocytes. Additionally, varying severity of adventitial edema, chronic inflammation, and fibrosis were observed. Focal to circumferential intimal thickening, enlarged endothelial cells, disruption of the internal elastic lamina with red blood cells, and inflammatory cells in subendothelial sites were observed in some affected arteries (Figure 4, E and F) . In studies of shorter duration (data not shown), microscopic coronary arterial lesions occurred in dogs given 50 µg/kg/minute for 12 or 24 hours, but lesions were not observed in dogs given 10 µg/kg/minute for 12 hours. Early lesions (12 and 24 hours) were similar in location and microscopic character but less severe. In general, atrial cardiomyocytes were morphologically unaltered, and there was no evidence of atrial infarction.



View larger version (111K):
[in this window]
[in a new window]
  		Figure 4. Heart from ETRA-infused dog. Note areas of hemorrhage in right atria (A) and right atrial appendage (B). Periarterial inflammation and fibrinoid necrosis of right extramural coronary arteries with inflammation extending into pericardial adipose tissue of the coronary groove (C and D). Multifocal areas of hemorrhage in tunica media of right coronary artery (E and F). H&E stain; original magnifications, x24 (C), x120 (D and E), x240 (F).

 
Toxicokinetics

Steady state plasma concentration of SB 209670 was achieved within 2 hours after initiation of infusion, was dose-proportional, and remained unchanged during the 5-day infusion period. Toxicokinetic data suggest that a steady state plasma concentration of ~5 µg/ml for 12 hours represents a threshold concentration, at or above which arterial lesions occurred (Table 1) .

ET Receptor Protein Expression

Dog atrial tissue had up to a 2.5-fold greater density of ET receptors as compared to the ventricles (Figure 5) . Within myocardial tissue, ETA receptor density was highest in right atria and second highest in left atria; ventricular tissue contained fewer ETA receptors and density in right and left ventricles was similar. Density of ETB receptors in right and left atria were similar but greater than that observed in right and left ventricles. Ratios of ETA:ETB receptors were ~1.2:1 in right atrium, 0.7:1 in the left atrium, and approximately 1:1 in the right and left ventricle (Table 3) . In comparison, values for ET receptors in coronary arteries were markedly increased above that measured for myocardial tissue (Figure 5) . Density of ETA receptors in LCA was 1.5-fold higher than values for RCA; ETB receptor density in RCA was threefold increased above that observed in LCA. The ratio of ETA:ETB in RCA was ~1:1, whereas this ratio in LCA was ~3.2:1.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 5. ETA and ETB receptor density in different regions of the normal dog heart. RCA, right coronary artery; LCA, left coronary artery; RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle.

 

View this table:
[in this window]
[in a new window]
  		Table 3. Summary of Endothelin Receptor Radioligand Binding Using [125I]ET-1 and 3

 
ET Receptor mRNA Expression

Quantitative real-time PCR analysis of ETA and ETB receptor mRNA expression in heart regions and coronary arteries is shown in Figure 6 . All values are relative to the expression measured in normal femoral artery as a control; absolute quantification of copy number was not done. ETA mRNA expression was greatest in right and left atria; values in RCA were higher than LCA but considerably lower than that expressed within atrial tissue. Values for ETA message from LCA and left ventricle were lower than those for femoral artery. ETB mRNA expression in RCA and right atria was 60- to 80-fold increased, respectively, and expression in left atria was about 40-fold above that of femoral artery. Expression in LCA and ventricular tissue was essentially comparable to control.



View larger version (17K):
[in this window]
[in a new window]
  		Figure 6. Quantitative analysis of ETA (A) and ETB (B) receptors mRNA by RT-PCR (Taqman) in normal dog heart and coronary arteries (n >= 3). The normal dog femoral artery (FA) was use as a reference base and values for all sites are expressed relative to ETA or ETB receptor mRNA abundance in FA.

 
The relative distribution of ET receptor mRNA in coronary arteries was confirmed by in situ hybridization. Hybridization signal for ETA receptor mRNA was weak and difficult to detect in both RCA and LCA. In contrast, an intense hybridization signal for ETB receptor mRNA was evident in RCA and of only limited expression in LCA, illustrated in Figure 7 . Hybridization signal for both ET receptors was localized predominantly to vascular smooth muscle of the media and intima of these arteries. No hybridization signal was evident using sense-strand riboprobes for either receptor.



View larger version (105K):
[in this window]
[in a new window]
  		Figure 7. Localization of ETB receptor mRNA expression in extramural coronary arteries of the dog. ETB anti-sense hybridization signal was localized predominantly to the vascular intima and media of the RCA (A). Hybridization signal was weak or absent in the LCA (C) as compared to the RCA (A), suggesting a lower density of ETB receptors in the LCA. Using ETB sense probes, hybridization signal was not observed in either LCA (B) or RCA (not shown). Dark field illumination; original magnifications, x130.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Data from this series of studies provide the first demonstration that regional cardiotoxicity is strongly associated with distribution of cellular receptors regulating vascular tone; specifically, distribution and frequency of ETA and ETB receptors within dog coronary arteries and immediate intramural branches predispose myocardial regions to damage. Regional receptor density and/or shifts in receptor subtype ratios can elicit an exaggerated physiological response to vasoactive agents. The right coronary vasculature and intramural atrial branches are sites of the dog heart predisposed to damage by vasodilator agents.

Regional damage by vasodilators has been best characterized in the dog because this species is frequently use in preclinical testing of novel pharmaceuticals.37 However, recognition of regional sensitivity to vasodilator-induced cardiotoxicity is not confined to the dog; similar observations have been made in monkeys38 and pigs.39 Interestingly, species difference of both region and size of vessel damaged have been reported after administration of minoxidil; in the pig, left atrial vessels with <=3 layers of medial smooth muscle are damaged, but in dogs, right atrial vessels with 3 to 10 layers of medial smooth muscle are most sensitive.39 Reasons for these differences in various species are unknown, but presumably relate to site-specific functional responsiveness. Previous reports from studies in dogs suggested that extreme increases in regional blood flow preceded atrial and coronary arterial damage. Humphrey et al40 and Mesfin et al5,41,42 5 reported that minoxidil, a long-acting vasodilator, when given to dogs at cardiotoxic doses induced a 6- to 10-fold increase in regional cardiac blood flow and that this sustained increase in flow resulted in damage to coronary vasculature. In a preliminary report we showed that the morphological observations in dogs given an ETRA (SB 207960) were very similar to those in dogs given minoxidil and to those in monkeys given another ETRA.6,7 The sixfold increase in right atrial flow, we reported in dogs given an ETRA were comparable to those of minoxidil. Consequently, it appears that vasodilators, when given to dogs, induced marked increases in regional blood flow which tended to precede evidence of cardiotoxicity.

Interestingly, in addition to markedly increasing regional myocardial blood flow, minoxidil when given to dogs also lowered MAP sufficiently to induce concomitant severe reflex tachycardia. This tachycardial event has been associated with additional pathological changes in heart, including subendocardial hemorrhage and papillary muscle necrosis.41 Since systemic hypotension and tachycardia were not observed in dogs given ETRA, it was not unusual that endocardial or papillary muscle lesions were not observed after ETRA exposure. In dogs given SB 207960, only minimal reductions in MAP (10–15 mmHg) and slight increases in HR (10–20%) were observed; these minimal changes were considered within the physiological range for the dog and consequently not expected to be associated with the ischemic type of myocardial damage associated with minoxidil administration.

Because cardiovascular lesions predominated in the RCA and right atrium of dogs given ETRAs, our working hypothesis was that ET receptors were most prevalent at these sites, thereby predisposing RCA and right atrium to damage during pharmacological manipulation of vascular tone. Comparison of blood flow between right atria, left atria and ventricular tissue indicated a six-, two-, and less than onefold increase, respectively, after infusion with ETRA; this reflects a marked difference in regional pharmacological responsiveness. Several investigators have demonstrated that the dog is pharmacologically responsive to endothelin and reported decreased coronary blood flow, increased coronary vascular resistance, and subsequent myocardial ischemia after endothelin challenge.16,20,24,32,43 Teerlink and coworkers,22 using anesthetized dogs, demonstrated after challenge with a selective ETB agonist that a transient period of vasodilation was followed by pronounced and sustained vasoconstriction of the left coronary artery; unfortunately, their observations were confined to the left coronary vascular bed and therefore comparison to the right vascular bed was not possible. Importantly, their observations indicated a potent ETB-mediated vasoconstrictor response in dog coronary artery, an observation which our findings, after ET receptor blockade, strongly support. Teerlink and coworkers used anesthetized dogs, a system which might have resulted in periods of unregulated cardiovascular responses; however, our results from unanesthetized dogs correlated well with those of Teerlink et al, suggesting minimal experimental consequences of anesthesia.

Morphological localization of ETB receptors in coronary arteries using in situ hybridization demonstrated an abundance of ETB receptor mRNA, predominantly in medial smooth muscle cells of coronary arteries, supporting findings that ETB receptors have a broader distribution than just within endothelium. Our observations are the first to emphasize the prevalence of ETB receptors in RCA versus LCA and consequently the potential difference in the role of ETB receptors in regulating blood flow to various myocardial regions. The prevalence of ETB receptors within RCA suggests ETB regulated vascular tone may be of more physiological importance in right heart vasculature than left. Our observations, as well as others, on blood flow alterations after challenge with either ET or ETRA certainly emphasized regional differences in pharmacological responsiveness, most likely mediated by a predominance of ETB receptors in these regions.

Characterization of ET receptor subtypes in dog coronary arteries was technically challenging since only the ETB receptor gene had been sequenced for dog. This report is the first to provide a partial nucleotide sequence for dog ETA receptor subtype, of sufficient specificity to allow production of ETA receptor signature probes for dog tissues (see Figure 1 ).44 This partial coding sequence was highly homologous to human ETA receptor sequence with 93 and 99% identity at the nucleotide and amino acid levels, respectively. Because G protein-coupled receptors (which include ET receptors) are highly regulated at the mRNA level and correlation of message expression with protein expression is unpredictable, it was our objective, first, to quantify both ETA and ETB receptor protein as the best measure of receptor abundance within selected sites and, second, to quantify message (mRNA) as a confirmatory indicator of a tissue’s ability to express selected receptors. Protein quantitation by immunoreactivity would have been the preferred approach; however, extensive alternative splicing and post-translation modification of ET receptors across species required the use of dog specific reagents, which were not available. Therefore, our approach was to quantify receptors using competitive radioligand binding; this approach technically compromised our ability to detect receptors pre-bound to endogenous ligand. Our results indicated, except for the abundance of message within atrial tissues, that protein receptor expression paralleled mRNA levels; this suggested ET receptor abundance was tightly coupled to message expression in the dog heart. The mismatch between protein and mRNA expression in atrial tissue may reflect limitation of the radioligand assay approach, in that an abundance of ET-1 production with subsequent endogenous ligand-receptor binding in atrial tissue probably resulted in an underestimation of receptor density and discordance between protein and message.

The ratio of ETA to ETB receptors at specific sites was initially considered a factor in predisposing sites to damage; however, the ratio of ETA to ETB within RCA was essentially 1:1 and quite similar ratios were observed in atrial and ventricular regions. In fact the only site with a markedly differing ratio of 3.4:1 was the LCA, which indicated a prevalence of ETA receptors in LCA. Our conclusion from assessment of ETA to ETB receptor ratios was that the ratio appeared less important than the overall abundance of ETB receptor at a particular site; the role of ETB receptors in regulating vascular tone appeared crucial in setting sensitivity of a site to vasodilator damage.

Radioligand receptor binding data indicated ETB receptors to be most prevalent in RCA, in fact, 3 times more prevalent than in LCA. The frequency of ETB receptors within atrial tissue was somewhat less than that observed in LCA, but twofold more frequent than observed in ventricular tissue; the ranking of cardiovascular sites evaluated in this study by prevalence of ETB receptor protein was RCA, LCA, atrial tissue, and ventricular tissue. Right versus left side differences were only observed for coronary arteries. Comparison of coronary arterial tissue for prevalence of message indicated RCA contained considerably more message for ETB receptors than LCA, and this corresponded to prevalence of protein. Regional frequency of cardiotoxic lesions also correlated closely with abundance of ETB receptor protein expression. ETB receptor mRNA was most prevalent in right heart (about similar in RCA and right atrium) followed by left atria, LCA, and ventricular tissue. The rank order of lesion occurrence and ETB receptor abundance correlated well and was RCA, LCA, and atrial tissue.

This is the first report in which ET receptor mRNA expression has been localized specifically to vascular smooth muscle of the dog coronary artery. These findings support and extend observations by others of an ET receptor subtype in the dog that mediates vasoconstriction and is expressed primarily in smooth muscle of the coronary vasculature.25 Based on gene homology and mRNA expression data, it is plausible that this ETB receptor subtype, which mediates vasoconstriction in the dog, is a homologue of the cloned human ETB receptor,15,45 a receptor previously described as the ET1 clearance receptor primarily localized to endothelium.12,18 Evidence now suggests obvious species differences in functionality of ETB receptors. In vitro studies in dog25 and pig46 coronary artery, rabbit veins,21 and rat systemic circulation32 indicate that ETB-like receptors do mediate vasoconstriction, but some organ variability in function occurs; the role as an ET1 clearance mechanism in various species is poorly defined. Hence the physiological effect of ET/ETB receptor signaling (ie, vasoconstriction, vasodilation, and/or ET1 clearance) can clearly differ between species and location of vascular bed. Consequently, one could predict that toxicological outcomes would also differ between sites and species.

It was not unexpected to find that ETB receptors mediate different functions or that differences occur between organ systems or animal species, since G protein-coupled receptors, which include the ET receptors, are generally known to have multiple, even dichotomous, functional roles.47,48 Receptors encoded by a single gene product but modified by post-transcriptional (mRNA splicing) and/or post-translational (glycosylation or phosphorylation) events can, as a consequence of these modifications, display multiple or disparate responses.19,47,49 Multiplicity of receptor functionality or variations between species can result from stimulation of differing G protein-coupled signal transduction systems50 or, alternatively, as recently proposed by McLatchie and coworkers, through involvement of varying receptor activity modifying proteins.51 Hence, as a result of G-protein subunit expression, receptor activity modifying proteins and the coordinated regulation of receptor expression, the biological response to receptor activation may vary widely between cells and/or species, as with, eg, ETB receptor stimulation mediating vasopressor, vasorelaxant, and/or ET clearance functionality. It is, therefore, important to balance gene protein and message expression data with measurements of biological response, because various and widely differing outcomes can result. The mere presence of message or protein will not consistently predict the responsiveness of a tissue or species to receptor ligand binding.

In conclusion, this series of studies quantifies ETA and ETB receptor protein and mRNA message at regional levels within dog heart and coronary arteries, ETB receptor protein was localized by in situ hybridization to vascular smooth muscle cells and demonstrated a marked prevalence of ETB receptor protein in the right coronary vascular bed. ET receptor subtype density was correlated with changes in regional blood flow during ETRA infusion and ultimately to a toxicological response. These studies provide a balanced data set of gene and protein expression in concert with regulatory effects on blood flow to ultimately explain a biological outcome. These data emphasize the importance of ETB receptor distribution in regulating vascular tone of the dog right coronary vasculature and the predisposition of this anatomical site to damage because of ETB receptor frequency.


   Acknowledgements
 
We thank Drs. Carrie A. Branch, William D. Kerns, and Heath C. Thomas for their scientific input to study design and review and interpretation of results, and James Alston and Tom Covatta for skillful technical assistance.


   Footnotes
 
Address reprint requests to Dr. Calvert Louden, SmithKline Beecham Pharmaceuticals UE0360, Department of Safety Assessment - US, P.O. Box 1359, King of Prussia, PA 19406. E-mail: Calvert_S_Louden{at}sbphrd.com

Accepted for publication March 10, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Dogterom P, Zbinden G, Reznik GK: Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview. CRC Crit Rev Toxicol 1992, 22:203-241
  2. Gans JH, Korson R, Cates MR, Ackerly CC: Effects of short-term and long term theobromine administration to male dogs. Toxicol Appl Pharmacol 1980, 53:481-496[Medline]
  3. Harlem JH, Joseph EC, Eden RJ, Walker TF, Major IR, Lamb MS: Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. Arch Toxicol 1986, 59:51-55[Medline]
  4. Herman EH, Balazs T, Young R, Earl FL, Krop S, Ferrans VJ: Acute cardiomyopathy induced by vasodilating antihypertensive agent minoxidil. Toxicol Appl Pharmacol 1979, 47:493-503[Medline]
  5. Mesfin GM, Shawaryn GG, Higgins MJ: Cardiovascular alterations in dogs treated with hydralazine. Toxicol Pathol 1987, 15:409-416[Medline]
  6. Louden C, Nambi P, Branch C, Gossett K, Pullen M, Eustis S, Solleveld H: Coronary arterial lesions in dogs treated with an endothelin receptor antagonist. J Cardiovasc Pharmacol 1998, 31(Suppl 1):S384-S385
  7. Louden C, Tierney L, Thomas R, Branch C, Schwartz L, Solleveld H: Coronary arterial lesions in dogs caused by endothelin receptor blockade are associated with regional differences in endothelin receptor distribution and blood flow. FASEB J 1999, 13:A156
  8. Yanagisawa M, Masaki T: Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol 1989, 38:1877-1883[Medline]
  9. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415[Medline]
  10. Adachi M, Yang YY, Furuichi Y, Miyamoto C: Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem Biophys Res Commun 1991, 180:1265-1272[Medline]
  11. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730-732[Medline]
  12. Battistini B, D’Orleans-Juste P, Sirois P: Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993, 68:600-628[Medline]
  13. Fukuroda T, Nishikibe M, Ohta Y, Ihara M, Yano M, Ishikawa K, Fukami Ikemoto F: Analysis of responses to endothelins in isolated porcine blood vessels by using a novel endothelin antagonist BQ153. Life Sci 1992, 50:PL107–PL112
  14. Harrison VJ, Randriantsoa A, Schoeffter P: Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol 1992, 105:511-513[Medline]
  15. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989, 86:2863-2867[Abstract/Free Full Text]
  16. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R: The endothelin ETB receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992, 186:867-873[Medline]
  17. Pernow J, Modin A: Endothelial regulation of coronary vascular tone in vitro: contribution of endothelin receptor subtypes and nitric oxide. Eur J Pharmacol 1993, 243:281-286[Medline]
  18. Chabrier PE: The role of endothelin in the vessel wall. Bailliere’s Clin Haematol 1993, 6:577-591[Medline]
  19. Sokolovsky M: Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signaling. Trends Biochem Sci 1991, 16:261-264[Medline]
  20. Igarashi Y, Aizawa Y, Tamura M, Ebe K, Yamaguchi T, Shibata A: Vasoconstrictor effect of endothelin on the canine coronary artery: is a novel endogenous peptide involved in regulating myocardial blood flow and coronary spasm? Am Heart J 1989, 118:674-678[Medline]
  21. Moreland S, McMullen DM, Delaney CL, Lee VG, Hunt JT: Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun 1992, 184:100-106[Medline]
  22. Teerlink JR, Breu V, Sprecher U, Clozel M, Clozel JP: Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 1994, 74:105-114[Abstract/Free Full Text]
  23. Summer MJ, Cannon TR, Mundin JW, White DG, Watts IS: Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992, 107:858-860[Medline]
  24. Rigel DF, Lappe RW: Differential responsiveness of conduit and resistance coronary arteries to endothelin A and B receptor stimulation in anesthetized dogs. J Cardiovasc Pharmacol 1993, 22(suppl 8):S243-S247
  25. Awane-Igata Y, Ikeda S, Watanabe T: Inhibitory effects of TAK-044 on endothelin induced vasoconstriction in various canine arteries and porcine coronary arteries: a comparison with selective ETA and ETB receptor antagonists. Br J Pharmacol 1997, 120:516-522[Medline]
  26. Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A, Leber JD, Cousins RD, Gao A, Peishoff CE, Bean JW, Eggleston D, Elshourbagy N, Kumar C, Lee JA, Brooks DP, Ruffolo RR, Jr, Feuerstein G, Weinstock J, Gleason JG, Elliott JD: SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994, 91:8052-8056[Abstract/Free Full Text]
  27. Bassingthwaighte JB, Malone MA, Moffett TC, King RB, Little SE, Link JM, Krohn KA: Validity of microsphere depositions for regional myocardial flows. Am J Physiol 1987, 253:H184-H193[Abstract/Free Full Text]
  28. Chien GL, Anselone CG, Davis RF, Van Winkle DM: Fluorescent vs. radioactive microsphere measurement of regional myocardial blood flow. Cardiovasc Res 1995, 30:405-412[Medline]
  29. Glenny RW, Bernard S, Brinkley M: Validation of fluorescent-labeled microspheres for measurement of regional organ perfusion. J Appl Physiol 1993, 74:2585-2597[Abstract/Free Full Text]
  30. Millard RW, Baig H, Vatner VF: Cardiovascular effects of radioactive microsphere suspensions and Tween 80 solutions. Am J Physiol 1977, 232:331-334
  31. Lu L, Gillet NA: An optimized protocol for an in situ hybridization using PCR-generated 33P-labeled riboprobes. Cell Vis 1994, 1:169-176
  32. Brooks DP, DePalma PD, Pullen M, Nambi P: Characterization of canine renal endothelin receptor subtypes and function. J Pharmacol Exp Ther 1994, 268:1091-1097[Abstract/Free Full Text]
  33. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156[Medline]
  34. Cyr C, Huebner K, Druck T, Kris R: Cloning and chromosomal localization of a human endothelin ETA receptor. Biochem Biophys Res Commun 1991, 181:184-190[Medline]
  35. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 1996, 6:986-994[Abstract/Free Full Text]
  36. Holland PM, Abramson R, Watson R, Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 1991, 88:7276-7280[Abstract/Free Full Text]
  37. Joseph EC, Mesfin G, Kerns WD: Pathogenesis of arterial lesions caused by vasoactive compounds in laboratory animals. Sipes IG McQueen CA Gandolfi AJ eds. Comprehensive Toxicology. 1997, :pp 279-307 Elsevier Science Ltd, Oxford
  38. Albassam MA, Metz AL, Gragtmans NJ, King LM, Macallum GE, Hallak H, McGuire EJ: Coronary arteriopathy in monkeys following administration of CI-1020, an endothelin A receptor antagonist. Toxicol Pathol 1999, 27:156-164[Abstract/Free Full Text]
  39. Herman EH, Ferrans VJ, Young RSK, Balazs T: A comparative study of minoxidil-induced myocardial lesions in beagle dogs and miniature swine. Toxicol Pathol 1989, 17:182-192[Medline]
  40. Humphrey SJ, Zins GR: Whole body and regional hemodynamic of minoxidil in conscious dogs. J Cardiovasc Pharmacol 1984, 6:979-988[Medline]
  41. Mesfin GM, Piper RC, DuCharme DW, Carlson RG, Humphrey SJ, Zins GR: Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol Pathol 1989, 17:164-181[Medline]
  42. Mesfin GM, Higgins MJ, Robinson FG, Zhong WZ: Relationship between serum concentrations, hemodynamic effects and cardiovascular lesions in dogs treated with minoxidil. Toxicol Appl Pharmacol 1996, 140:337-344[Medline]
  43. Clozel JP, Clozel M: Effects of endothelin on the coronary vascular bed in open-chest dogs. Circ Res 1989, 65:1193-1200[Abstract/Free Full Text]
  44. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning and expression of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348:732-735[Medline]
  45. Arai H, Nakao K, Takaya K, Hosoda K, Ogawa Y, Nakanishi S, Imura H: The human endothelin-B receptor gene: structural organization and chromosomal assignment. J Biol Chem 1993, 268:3463-3470[Abstract/Free Full Text]
  46. Dagassan PH, Breu V, Clozel M, Kunzli A, Vogt P, Turina M, Kiowski W, Clozel JP: Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996, 27:147-153[Medline]
  47. Karoor V, Shih M, Tholanikunnel B, Malbon CC: Regulating expression and function of G-protein-linked receptors. Prog Neurobiol 1996, 48:555-568[Medline]
  48. Huggins JP, Pelton JT, Miller RC: The structure and specificity of endothelin receptors: their importance in physiology and medicine. Pharmacol Ther 1993, 59:55-123[Medline]
  49. Miyamoto Y, Yoshimasa T, Arai H, Takaya K, Ogawa Y, Itoh H, Nakao K: Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts. Biochem J 1996, 313:795-801
  50. Ozaki S, Ihara M, Saeki T, Fukami T, Ishikawa K, Yano M: Endothelin ETB receptors couple to two distinct signaling pathways in porcine kidney epithelial LLC-PK1 cells. J Pharmacol Exp Ther 1994, 270:1035-1040[Abstract/Free Full Text]
  51. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393:333-339[Medline]



This article has been cited by other articles:


Home page
 Toxicol PatholHome page
C. Louden, D. Brott, A. Katein, T. Kelly, S. Gould, H. Jones, G. Betton, J.-P. Valetin, and R. J. Richardson
Biomarkers and Mechanisms of Drug-Induced Vascular Injury in Non-Rodents
Toxicol Pathol, January 1, 2006; 34(1): 19 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
H. B. Jones, A. Macpherson, G. R. Betton, A. S. Davis, R. Siddall, and P. Greaves
Endothelin Antagonist-Induced Coronary and Systemic Arteritis in the Beagle Dog
Toxicol Pathol, April 1, 2003; 31(3): 263 - 272.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
F. A.S. Clemo, W. E. Evering, P. W. Snyder, and M. A. Albassam
Differentiating Spontaneous from Drug-Induced Vascular Injury in the Dog
Toxicol Pathol, January 1, 2003; 31(1_suppl): 25 - 31.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
M. A. Albassam, A. L. Metz, R. E. Potoczak, K. P. Gallagher, S. Haleen, H. Hallak, and E. J. Mcguire
Studies on Coronary Arteriopathy in Dogs Following Administration of CI-1020, an Endothelin A Receptor Antagonist
Toxicol Pathol, April 1, 2001; 29(3): 277 - 284.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louden, C. S.
Right arrow Articles by Schwartz, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louden, C. S.
Right arrow Articles by Schwartz, L. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS